Pawińska Katarzyna, Balwierz Walentyna, Baran Jarosław
Klinika Onkologii i Hematologii Dzieciecej Polsko-Amerykański Instytut Pediatrii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Przegl Lek. 2006;63(1):41-3.
Monitoring of residual leukemic cells, so called minimal residual disease (MRD) in acute leukemias is of great importance in clinical practice. Especially evaluation of early response to treatment has a important prognostic value, and modifies the therapy schedule in a nowadays used treatment protocols. Methods used for monitoring of MRD consist of molecular techniques, which detect chromosomal aberrations or immunoglobulins and lymphocyte T receptor genes rearrangements, as well as method of flow cytometry, which detect immunophenotype typical for the leucemic clone. The paper shows advantages and disadvantages each of those methods. The best approach to monitoring MRD in ALL during and after the treatment seems to be combination of molecular and immunological techniques.
监测急性白血病中的残留白血病细胞，即所谓的微小残留病（MRD），在临床实践中具有重要意义。特别是评估早期治疗反应具有重要的预后价值，并可在当前使用的治疗方案中调整治疗计划。用于监测MRD的方法包括检测染色体畸变或免疫球蛋白和淋巴细胞T受体基因重排的分子技术，以及检测白血病克隆典型免疫表型的流式细胞术方法。本文展示了这些方法各自的优缺点。在急性淋巴细胞白血病（ALL）治疗期间及之后监测MRD的最佳方法似乎是分子技术与免疫技术相结合。
